This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Chugai Seiyaku Kabushiki Kaisha, Hoffmann-La Roche Inc.. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:


Years Active: 2025
Title: The Innovations of Robert Kopf
Introduction
Robert Kopf is a notable inventor based in Basel, Switzerland. He has made significant contributions to the field of pharmaceuticals, particularly in the development of formulations that enhance therapeutic efficacy. His work has been recognized for its potential to improve treatment options for patients.
Latest Patents
Robert Kopf holds a patent for a pharmaceutical formulation comprising an aqueous solution of an antibody. This innovative formulation is designed to reduce particle formation and includes a bispecific monoclonal antibody that substitutes for coagulation factor VIII. Additionally, it features an anti-IL-6 receptor antibody that inhibits binding to the interleukin 6 receptor. This formulation also incorporates a polyoxyethylene polyoxypropylene glycol (poloxamer), showcasing his commitment to advancing pharmaceutical technology. He has 1 patent to his name.
Career Highlights
Throughout his career, Robert Kopf has worked with prominent companies in the pharmaceutical industry. Notably, he has been associated with Chugai Seiyaku Kabushiki Kaisha and Hoffmann-La Roche Inc. His experience in these organizations has contributed to his expertise in drug formulation and development.
Collaborations
Robert has collaborated with esteemed colleagues, including Kohei Soeda and Masakazu Fukuda. These partnerships have facilitated the exchange of ideas and innovations, further enhancing the impact of his work in the pharmaceutical sector.
Conclusion
Robert Kopf's contributions to pharmaceutical formulations demonstrate his innovative spirit and dedication to improving healthcare solutions. His work continues to influence the industry and offers promising advancements for future therapies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile